Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest

A multi-kinase inhibitor, rigosertib (ON 01910.Na) has recently been highlighted as a novel type of anti-cancer agent for the treatment of the myelodysplastic syndromes (MDS), but its action mechanisms remain to be clarified. We investigated the in vitro effects of rigosertib on an MDS-derived cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyoda, Tomoko, Tsujioka, Takayuki, Nakahara, Takako, Suemori, Shin-ichiro, Okamoto, Shuichiro, Kataoka, Mikio, Tohyama, Kaoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376437/
https://www.ncbi.nlm.nih.gov/pubmed/25580850
http://dx.doi.org/10.1111/cas.12605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376437/
https://www.ncbi.nlm.nih.gov/pubmed/25580850
http://dx.doi.org/10.1111/cas.12605

Ejemplares similares